Citing limitations in the study, Novo Nordisk, which makes the drugs included in the claims analysis, said in a statement reported by Reuters that it does not believe these data are sufficient to draw conclusions about overall patient adherence and persistence to various GLP-1 medicines, including our treatments. Nonetheless, the problem of lack of patient persistence on GLP-1s under real-world conditions, examined and published by a growing number of sources, isnt going away
Megimine 2500 Injection by Green Cross Remedies is a reliable methylcobalamin injection from a trusted leading Vitamin B12 injection manufacturer in India
SOUL Published in the New England Journal of Medicine , SOUL was a double-blind, placebo-controlled, event-driven superiority trial, enrolling 9650 participants who were randomised to receive oral semaglutide (up to 14 mg once daily) or placebo, alongside standard care for diabetes and CVD (McGuire et al, 2025)
Therapeutic potential of Semaglutide, a newer GLP-1 receptor agonist, in abating obesity, non-alcoholic steatohepatitis and neurodegenerative diseases: a narrative review
Our comprehensive lab testing allows us to evaluate key systems that impact your health, from hormonal balance to gut function and nutrient status
